fig2
Figure 2. ROS1 mutation as a predictor of ICI resistance in patients with HNC. (A) Kaplan-Meier survival curves comparing OS between ROS1-Mut and ROS1-WT groups in the ICI-treated HNC cohort; (B) Multivariate analysis of OS in the ICI-treated HNC cohort. ICI: Immune checkpoint inhibitor; HNC: head and neck cancer; OS: overall survival; ROS1-Mut: ROS1 mutations; ROS1-WT: ROS1-wild-type.
